Clarithromycin

Product Story

Clarithromycin was discovered in the 1970s at Taisho Pharmaceutical Co. in Japan by a research team led by Dr. Shigeo Morimoto, who systematically modified the erythromycin molecule to overcome its key clinical limitations. The breakthrough was the selective methylation of the C-6 hydroxyl group of erythromycin A, producing 6-O-methylerythromycin A — later named clarithromycin. This single structural modification prevented the acid-catalyzed intramolecular cyclization that degraded erythromycin in the stomach, which had caused poor and unpredictable oral bioavailability. Taisho licensed the compound to Abbott Laboratories (now AbbVie) for global development, and it was launched as Biaxin/Klacid in 1991. Clarithromycin became the first macrolide with acid stability sufficient for reliable oral dosing without enteric coating.

Clarithromycin's mechanism of action follows the classic macrolide pathway: it reversibly binds to the 50S ribosomal subunit near the peptidyl transferase center, blocking the exit tunnel for nascent polypeptide chains and inhibiting bacterial protein synthesis. What distinguishes clarithromycin pharmacologically is its active metabolite — 14-(R)-hydroxyclarithromycin, produced by hepatic CYP3A4 metabolism — which retains antimicrobial activity and acts synergistically with the parent compound, particularly against H. influenzae. This metabolite-mediated synergy effectively doubles clarithromycin's potency against certain respiratory pathogens. The 14-membered lactone ring macrolides (clarithromycin, erythromycin) are also notable for their motilin-receptor agonist activity, which accounts for their gastrointestinal prokinetic effects.

Clarithromycin's defining clinical role is in H. pylori eradication, where it is the cornerstone macrolide component of standard triple therapy (clarithromycin + amoxicillin + proton pump inhibitor) worldwide. Its acid stability and high gastric mucosal concentrations make it the preferred macrolide for this indication. Beyond H. pylori, clarithromycin is a key agent for community-acquired respiratory infections, atypical mycobacterial disease (particularly Mycobacterium avium complex), and — through its immunomodulatory properties — in the long-term management of diffuse panbronchiolitis and chronic rhinosinusitis. However, it is also a potent inhibitor of CYP3A4, which creates clinically significant drug-drug interactions with statins, calcium channel blockers, and many other medications.

As of mid-2026, global clarithromycin API demand is estimated at 2,500-3,500 metric tons annually. The market has been shaped by two opposing forces: growing H. pylori treatment volumes in Asia and increasing clarithromycin resistance rates that are driving some guidelines toward alternative regimens. China, India, and select European manufacturers dominate production, with Chinese manufacturers controlling the upstream erythromycin A fermentation and semi-synthetic conversion chain. Generic erosion since patent expiry (2005 in the US) has created a highly competitive, price-sensitive API market. KingWish supplies GMP-certified clarithromycin meeting EP/USP/IP/CP standards, with consistent particle size and polymorphic form control for reliable formulation performance.

Quality Specifications

Therapeutic Applications

• H. pylori eradication: Cornerstone component of standard triple therapy (clarithromycin 500 mg + amoxicillin 1 g + PPI, BID for 7-14 days). Resistance testing recommended where local clarithromycin resistance exceeds 15%.
• Community-acquired pneumonia: Oral macrolide for CAP caused by S. pneumoniae, H. influenzae, M. catarrhalis, and atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella).
• Upper respiratory infections: Treatment of streptococcal pharyngitis, acute sinusitis, and acute otitis media, particularly in penicillin-allergic patients.
• Mycobacterium avium complex (MAC): Prophylaxis and combination treatment of disseminated MAC in HIV/AIDS patients, typically with ethambutol +/- rifabutin. Also used for MAC pulmonary disease in non-HIV patients.
• Skin and soft tissue infections: Effective for uncomplicated skin infections caused by S. aureus and S. pyogenes, particularly in patients with beta-lactam allergies.